Afrezza
| Autor: | Diane S. Aschenbrenner |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Type 1 diabetes business.industry Insulin medicine.medical_treatment Inhaler Inhaled insulin General Medicine Type 2 diabetes medicine.disease Insulin -- Administration and Dosage Lung disease Internal medicine Administration Inhalation medicine Intensive care medicine business Before Meals Insulin -- Adverse Effects General Nursing Asthma |
| Zdroj: | AJN, American Journal of Nursing. 114:22-23 |
| ISSN: | 0002-936X |
| DOI: | 10.1097/01.naj.0000454844.50727.76 |
| Popis: | Afrezza (insulin human) is a newly approved fast-acting inhaled insulin. It can be used in treating type 1 diabetes when added to a long-acting insulin; in studies, patients with type 2 diabetes used it in combination with oral antidiabetic therapy. Afrezza will be available in 2015. Afrezza is taken before meals using a small, specially designed inhaler. Patients should be carefully assessed for lung disease prior to starting Afrezza therapy. Chronic obstructive pulmonary disease and asthma are contraindications to use. Lung function can deteriorate after therapy begins. https://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=107830773&site=eds-live&scope=site |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|